24 October 2016 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
14 September 2016 ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award
12 September 2016 Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting
1 September 2016 Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016
8 August 2016 ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
5 July 2016 Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications